Simon Gaisford
Overview
Explore the profile of Simon Gaisford including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
161
Citations
3457
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Austin P, Gaisford S, Elia M
Nutrition
. 2024 Jan;
119:112319.
PMID: 38194818
Objectives: Because bloodstream infection and venous catheter (or cannula) bloodstream infection are associated with high morbidity and cost, early identification and treatment are important. Isothermal microcalorimetry can detect microbial growth...
12.
Elbadawi M, Li H, Basit A, Gaisford S
Int J Pharm
. 2024 Jan;
652:123741.
PMID: 38181989
Artificial intelligence (AI) is a revolutionary technology that is finding wide application across numerous sectors. Large language models (LLMs) are an emerging subset technology of AI and have been developed...
13.
Sun S, E Alkahtani M, Gaisford S, Basit A, Elbadawi M, Orlu M
Pharmaceutics
. 2023 Nov;
15(11).
PMID: 38004607
Three-dimensional (3D) printing is an advanced pharmaceutical manufacturing technology, and concerted efforts are underway to establish its applicability to various industries. However, for any technology to achieve widespread adoption, robustness...
14.
E Alkahtani M, Elbadawi M, Chapman C, Green R, Gaisford S, Orlu M, et al.
Adv Healthc Mater
. 2023 Oct;
13(3):e2301759.
PMID: 37861058
Conductive materials have played a significant role in advancing society into the digital era. Such materials are able to harness the power of electricity and are used to control many...
15.
Pang Y, Gaisford S, Magdysyuk O, Williams G
Int J Pharm X
. 2023 Aug;
6:100200.
PMID: 37564112
The combination of poorly-soluble drugs with small molecule co-formers to generate amorphous solid dispersions (ASDs) has great potential to improve dissolution rate and kinetic solubility, and thus increase the bioavailability...
16.
Ong J, Chow Y, Gaisford S, Cook M, Swift T, Telford R, et al.
Int J Pharm
. 2023 Aug;
643:123286.
PMID: 37532009
Vat photopolymerization has garnered interest from pharmaceutical researchers for the fabrication of personalised medicines, especially for drugs that require high precision dosing or are heat labile. However, the 3D printed...
17.
Awad A, Goyanes A, Orlu M, Gaisford S, Basit A
Int J Pharm X
. 2023 Jul;
5:100176.
PMID: 37396625
Infliximab is a monoclonal antibody that plays an important role in the management and treatment of chronic inflammatory bowel diseases (IBD). Due to its macromolecular structure, its delivery through the...
18.
Seoane-Viano I, Xu X, Ong J, Teyeb A, Gaisford S, Campos-Alvarez A, et al.
Int J Pharm X
. 2023 Jul;
5:100184.
PMID: 37396623
Pharmaceutical 3D printing (3DP) is one of the emerging enabling technologies of personalised medicines as it affords the ability to fabricate highly versatile dosage forms. In the past 2 years,...
19.
Al Rahal O, Kariuki B, Hughes C, Williams P, Xu X, Gaisford S, et al.
Cryst Growth Des
. 2023 May;
23(5):3820-3833.
PMID: 37159655
Phase transitions in crystalline molecular solids have important implications in the fundamental understanding of materials properties and in the development of materials applications. Herein, we report the solid-state phase transition...
20.
Elbadawi M, Basit A, Gaisford S
Int J Pharm
. 2023 Apr;
639:122926.
PMID: 37030639
Achieving carbon neutrality is seen as an important goal in order to mitigate the effects of climate change, as carbon dioxide is a major greenhouse gas that contributes to global...